Zelira Therapeutics Limited
ZLDAF
$0.2992
$0.041616.15%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | -98.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | -98.50% | |||
| Cost of Revenue | 0.00% | -98.65% | |||
| Gross Profit | 0.00% | 98.69% | |||
| SG&A Expenses | 2.71% | -126.29% | |||
| Depreciation & Amortization | -2.78% | -24.59% | |||
| Other Operating Expenses | -2.80% | 552.11% | |||
| Total Operating Expenses | -2.76% | -45.25% | |||
| Operating Income | 2.74% | 44.46% | |||
| Income Before Tax | 2.75% | -4.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.75% | -4.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -2.83% | 541.07% | |||
| Net Income | 2.75% | -0.70% | |||
| EBIT | 2.74% | 44.46% | |||
| EBITDA | 2.76% | 44.91% | |||
| EPS Basic | 2.81% | -0.71% | |||
| Normalized Basic EPS | 2.75% | 1.58% | |||
| EPS Diluted | 2.81% | -0.71% | |||
| Normalized Diluted EPS | 2.75% | 1.58% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||